Favorable initial results from a phase 1/2 trial of solnerstotug in PD-L1–resistant tumors showed a 14% response rate and 62% ...

Initial clinical activity in a PD-(L)1 resistant population, with an ORR almost three times higher than historical PD-(L)1 rechallenge response ...

Sensei Biotherapeutics' solnerstotug shows a 14% ORR in PD-(L)1 resistant tumors and remains well tolerated in early trial data from its Phase 1/2 study.

Preliminary efficacy data from Phase 1/2 dose expansion cohort show durable responses and tumor shrinkage in a PD-(L)1 resistant “hot” tumor ...

Sensei Biotherapeutics, Inc. (NASDAQ: SNSE) shares started out sharply higher Friday. The Boston-based clinical stage biotechnology company focused on the discovery and development of next-generation ...

The initial 14% response rate seen with solnerstotug is nearly three times higher than what would typically be expected in this setting. We believe these early data suggest solnerstotug may ...

In PD-(L)1 resistant hot tumors, solnerstotug+cemiplimab showed 14% ORR, nearly 3x higher than historical PD-(L)1 rechallenge response rates Solnerstotug remains well tolerated, with no dose ...